Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mim8 phase 3 prophylaxis trial in adolescents and adults with haemophilia A
NL-OMON51871Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of denecimig in hemophilia A (4 arms), sponsored by Novo Nordisk. Primary endpoints: Number of treated bleeds in subjects with no prophylaxis treatment and Number of treated bleeds in subjects with prior prophylaxis treatment. Started Mar 2022; status: active, not recruiting.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON51871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51871.